Overcoming genetically-based resistance mechanisms to PD-1 blockade

An intratumoral TRIL-9 agonist (SD101) leads to resistance in MC38 tumor mutants

The IFN-gamma-induced increased expression of antigen presenting machinery, IFN-gamma signaling and chemokines is lost with JAK/12 LoF mutations.

Results

JAK/12 LoF mutations result in insensitivity to IFN induced antimetastatic effects, but does not impair T cell activation and cytoxicity, while Blm tumor results in lack of antigen presentation to T cells and loss of antitumor activity.

Overcoming resistance to PD-1 blockade

An intratumoral TRIL-9 agonist (SD101) leads to resistance in MC38 tumor mutants

The IFN-gamma-induced increased expression of antigen presenting machinery, IFN-gamma signaling and chemokines is lost with JAK/12 LoF mutations.

Results

JAK/12 LoF mutations result in insensitivity to IFN induced antimetastatic effects, but does not impair T cell activation and cytoxicity, while Blm tumor results in lack of antigen presentation to T cells and loss of antitumor activity.

Overcoming resistance to PD-1 blockade

An intratumoral TRIL-9 agonist (SD101) leads to resistance in MC38 tumor mutants

The IFN-gamma-induced increased expression of antigen presenting machinery, IFN-gamma signaling and chemokines is lost with JAK/12 LoF mutations.

Results

JAK/12 LoF mutations result in insensitivity to IFN induced antimetastatic effects, but does not impair T cell activation and cytoxicity, while Blm tumor results in lack of antigen presentation to T cells and loss of antitumor activity.

Overcoming resistance to PD-1 blockade

An intratumoral TRIL-9 agonist (SD101) leads to resistance in MC38 tumor mutants

The IFN-gamma-induced increased expression of antigen presenting machinery, IFN-gamma signaling and chemokines is lost with JAK/12 LoF mutations.

Results

JAK/12 LoF mutations result in insensitivity to IFN induced antimetastatic effects, but does not impair T cell activation and cytoxicity, while Blm tumor results in lack of antigen presentation to T cells and loss of antitumor activity.

Overcoming resistance to PD-1 blockade

An intratumoral TRIL-9 agonist (SD101) leads to resistance in MC38 tumor mutants

The IFN-gamma-induced increased expression of antigen presenting machinery, IFN-gamma signaling and chemokines is lost with JAK/12 LoF mutations.

Results

JAK/12 LoF mutations result in insensitivity to IFN induced antimetastatic effects, but does not impair T cell activation and cytoxicity, while Blm tumor results in lack of antigen presentation to T cells and loss of antitumor activity.